Labyrinthitis, also known as vestibular neuritis, is an inflammation of the inner earor the nerves that connect the inner ear to the brain due to a variety of reasons such as infection by measles, mumps, trauma, autoimmune etc.
Labyrinthitis shows various symptoms such as hearing loss, speech problems, double vision, abnormal gait, dizziness, nystagmus (rapid and undesired eye motion), vertigo, ringing in the ears, etc. Labyrinthitis is triggered by cold flu and occur as a single attack, or a series of attacks, which generally resolves on its own over three to six weeks.

The global Labyrinthitis market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Labyrinthitis volume and value at global level, regional level and company level. From a global perspective, this report represents overall Labyrinthitis market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Labyrinthitis in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Labyrinthitis manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Merck
Sanofi
Teva Pharmaceutical
Mylan
Eli Lilly
Sun Pharmaceutical
Shandong Taihua
Cipla

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Autoimmune Labyrinthitis
Infective Labyrinthitis

Segment by Application
Hospitals
Clinics
Other